Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Durand

Showing results (111-120 of 176) with videos related to

Pageof 18
Sort By:
Investigational New Drugs|May 27, 2011
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patientsOlivier Mir, Jérôme Alexandre, Romain Coriat, et al.
The Oncologist|August 3, 2011
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activityOlivier Mir, Romain Coriat, Laure Cabanes, et al.
Annals of Neurology|January 12, 2017
Pseudofeeders on fetal magnetic resonance imaging predict outcome in vein of Galen malformationsGuillaume Saliou, Irène Vraka, Jean-Paul Teglas, et al.
Anti-Cancer Drugs|June 16, 2012
Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2Olivier Mir, Romain Coriat, Marion Dhooge, et al.
Annals of Intensive Care|October 14, 2020
pCLIF-SOFA is a reliable outcome prognostication score of critically ill children with cirrhosis: an ESPNIC multicentre studyCaroline Claude, Akash Deep, Martin Kneyber, et al.
Annals of Nutrition & Metabolism|December 23, 2019
Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung CancerGuillaume Ulmann, Anne Jouinot, Camille Tlemsani, et al.
Journal of the American Chemical Society|January 5, 2016
Prototypes of Lanthanide(III) Agents Responsive to Enzymatic Activities in Three Complementary Imaging Modalities: Visible/Near-Infrared Luminescence, PARACEST-, and T1-MRIJiefang He, Célia S Bonnet, Svetlana V Eliseeva, et al.
Medical Oncology (Northwood, London, England)|March 20, 2012
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenibOlivier Mir, Romain Coriat, Pascaline Boudou-Rouquette, et al.
Molecular and Cellular Biology|June 17, 2004
CCR4-associated factor CAF1 is an essential factor for spermatogenesisCyril Berthet, Anne-Marie Morera, Marie-Jeanne Asensio, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|October 12, 2017
Dynamic Structuration of Physical Chitosan HydrogelsNicolas Sereni, Alin Enache, Guillaume Sudre, et al.
Pageof 18

Showing results (111-120 of 176) with videos related to

Sort By:
Pageof 18
Investigational New Drugs|May 27, 2011
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patientsOlivier Mir, Jérôme Alexandre, Romain Coriat, et al.
The Oncologist|August 3, 2011
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activityOlivier Mir, Romain Coriat, Laure Cabanes, et al.
Annals of Neurology|January 12, 2017
Pseudofeeders on fetal magnetic resonance imaging predict outcome in vein of Galen malformationsGuillaume Saliou, Irène Vraka, Jean-Paul Teglas, et al.
Anti-Cancer Drugs|June 16, 2012
Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2Olivier Mir, Romain Coriat, Marion Dhooge, et al.
Annals of Intensive Care|October 14, 2020
pCLIF-SOFA is a reliable outcome prognostication score of critically ill children with cirrhosis: an ESPNIC multicentre studyCaroline Claude, Akash Deep, Martin Kneyber, et al.
Annals of Nutrition & Metabolism|December 23, 2019
Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung CancerGuillaume Ulmann, Anne Jouinot, Camille Tlemsani, et al.
Journal of the American Chemical Society|January 5, 2016
Prototypes of Lanthanide(III) Agents Responsive to Enzymatic Activities in Three Complementary Imaging Modalities: Visible/Near-Infrared Luminescence, PARACEST-, and T1-MRIJiefang He, Célia S Bonnet, Svetlana V Eliseeva, et al.
Medical Oncology (Northwood, London, England)|March 20, 2012
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenibOlivier Mir, Romain Coriat, Pascaline Boudou-Rouquette, et al.
Molecular and Cellular Biology|June 17, 2004
CCR4-associated factor CAF1 is an essential factor for spermatogenesisCyril Berthet, Anne-Marie Morera, Marie-Jeanne Asensio, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|October 12, 2017
Dynamic Structuration of Physical Chitosan HydrogelsNicolas Sereni, Alin Enache, Guillaume Sudre, et al.
Pageof 18